3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
11
Gastrointestinal
5
Lymphoid
2
Conditions
Lymphoproliferative Disorders
2
Anemia, Iron-Deficiency
2
Anemia
2
Interventions
Epoetin Alfa
10
fludarabine phosphate
3
Darbepoetin alfa
3
Cyclophosphamide
3
fludarabine
2
ferric carboxymaltose
2
Thiotepa
2
Therapeutics
2
Filgrastim
2
Ferric Oxide, Saccharated
2
Cyclosporine
2
Busulfan
2
Antilymphocyte Serum
2
AP 1903 reagent
2
venetoclax
1
trametinib
1
thymoglobulin
1
siltuximab
1
ruxolitinib
1
regorafenib
1
ponatinib
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
olaparib
1
obinutuzumab
1
neratinib
1
lorlatinib
1
lenvatinib
1
idelalisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Anemia
×
ferric carboxymaltose
×
Lymphoid
×
Clear all
NCT01100879
2022-05-09
AOC-MM
Vifor Pharma
Phase 4
Terminated
3 enrolled
NCT01101399
2013-12-18
FID-CHEMO
Vifor Pharma
Phase 3
Completed
19 enrolled